Alone or in combination with other drugs, PI3Kα inhibitors prevent tumor growth particularly in estrogen receptor alpha (ERα)-positive breast cancers, but depending on the type of the PI3Kα mutation different therapeutic regimes must be followed13. Here, ESR1 is linked to breast carcinoma.